Table 8 Indications for DPTs
| Â | Europe, n (%) | Asia Pacific, n (%) | North America, n (%) | Latin America, n (%) | Africa Middle East, n (%) | Region Not Specified, n (%) | Total (n = 65), n (%) |
|---|---|---|---|---|---|---|---|
Exclude hypersensitivity (non-suggestive history/non-specific symptoms) | 22 (33.5) | 10 (15.4) | 4 (6.2) | 4 (6.2) | 2 (3.1) | 5 (7.7) | 50 (76.9) |
Definitive diagnosis in suggestive history with negative, non-conclusive or non-available allergological tests | 22 (33.8) | 9 (13.8) | 4 (6.2) | 5 (7.7) | 4 (6.2) | 0 (0.0) | 44 (67.7) |
Exclude cross-reactivity of related drugs in proven hypersensitivity (e.g. cephalosporin in a penicillin allergic individual) | 22 (33.8) | 8 (12.3) | 4 (6.2) | 3 (4.6) | 2 (3.1) | 2 (3.1) | 41 (63.1) |
Provide safe pharmacologically/structurally non-related drugs in proven hypersensitivity (e.g. beta-lactams) | 21 (32.3) | 5 (7.7) | 5 (7.7) | 3 (4.6) | 2 (3.1) | 3 (4.6) | 39 (60.0) |